经中国证监会《关于核准海南珠江控股股份有限公司向北京粮食集团有限责任公司 等发行股份购买资产并募集配套资金的批复》（证监许可〔2017〕1391 号）核准，同 意公司非公开发行不超过 48,965,408 股新股，发行价 8.82 元/股，募集配套资金总额不 超过人民币 43,187.49 万元。京粮控股实际募集资金总额为人民币 431,874,898.56 元， 扣除发行费用人民币 45,000,000.00 元，募集资金净额为人民币 386,874,898.56 元。上述 募集资金已全部到位，并由中兴华会计师事务所（特殊普通合伙）于 2017 年 10 月 16 日出具的《验资报告》（中兴华验字(2017) 第 010120 号）审验确认。京粮控股对募集 资金实行专户存储，并与独立财务顾问、募集资金开户行签署了募集资金三方监管协议。 东兴证券股份有限公司 关于海南京粮控股股份有限公司 募集资金投资项目延期的核查意见 京粮控股于 2023 年 11 月 21 日分别召开了第十届董事会第九次会议和第十届监事 会第八次会议，并于 2023 年 12 月 8 日召开了 2023 年第二次临时股东大会，审议通过 了 ...

Core Viewpoint - Dongxing Securities successfully issued "2025 Technology Innovation Corporate Bonds (First Phase)" with a scale of 1 billion yuan and a term of 3 years at a coupon rate of 1.80%, reflecting strong market recognition of its operational capabilities and future development [1] Group 1: Bond Issuance Details - The bond issuance was met with enthusiastic subscription from market investors, achieving a subscription multiple of 3.94 [1] - The issuance rate is significantly lower than that of similar securities companies' bonds with the same term, indicating market confidence in Dongxing Securities [1] Group 2: Strategic Implications - The bond issuance aligns with the national innovation-driven development strategy, with raised funds earmarked for investment in the technology innovation sector [1] - Dongxing Securities is committed to the "Technology Finance" development concept, demonstrating its determination to support technological innovation and serve the real economy [1] Group 3: Future Plans - The company plans to continue expanding financing channels and optimizing its financing structure to support high-quality development [1] - Dongxing Securities aims to contribute more significantly to the national innovation-driven development strategy [1]

Core Viewpoint - Dongya Pharmaceutical (605177.SH) is expected to report a significant loss in the first half of 2025, with net profit projected to be between -28 million to -35 million yuan, contrasting sharply with a profit of 32.47 million yuan in the same period last year [1][2]. Financial Performance - In 2024, the company reported operating revenue of 1.198 billion yuan, a decrease of 11.66% year-on-year [2]. - The net profit attributable to shareholders was -101 million yuan, representing a year-on-year decline of 183.02% [2]. - The net profit after excluding non-recurring gains and losses was -98.41 million yuan, down 191.03% year-on-year [2]. - The net cash flow from operating activities was -157 million yuan [2]. Shareholder Structure - The actual controllers of Dongya Pharmaceutical are Chi Zhengming and Chi Cheng, who together hold significant voting rights in the company [1]. - Chi Zhengming directly owns 41.06% of the shares, while Chi Cheng holds 6.79% directly and has additional influence through a partnership [1]. Fundraising and Use of Proceeds - Dongya Pharmaceutical has raised a total of 1.574 billion yuan through two fundraising rounds since its listing [4]. - The company raised 688 million yuan through the issuance of convertible bonds, with a net amount of approximately 680 million yuan after deducting issuance costs [3]. - The funds raised are allocated for projects including the production of key intermediates for cephalosporin antibiotics and upgrading raw material production [2].

Core Viewpoint - 华夏航空's stock is currently trading at 8.55 yuan, reflecting a decline of 2.40% and is in a state of breaking its initial public offering price [1] Fundraising Activities - In March 2018, 华夏航空 was listed on the Shenzhen Stock Exchange, raising a total of 83.592 million yuan from the issuance of 40.5 million shares at a price of 20.64 yuan per share, with a net amount of 77.038 million yuan after expenses [1] - In October 2019, the company issued 790,000 convertible bonds with a total fundraising amount of 79 million yuan, resulting in a net amount of 77.456 million yuan after deducting issuance costs [2] - In 2022, 华夏航空 conducted a non-public offering of A-shares, issuing 264,673,906 shares at a price of 9.20 yuan per share, raising a total of approximately 2.435 billion yuan, with a net amount of about 2.410 billion yuan after expenses [3] Total Fundraising - The total amount raised by 华夏航空 from the three fundraising activities is approximately 406.092 million yuan [4] Dividend Distribution - On April 16, 2019, 华夏航空 announced a dividend plan of 1.3 yuan per 10 shares and a bonus issue of 5 shares for every 10 shares held [4] - On July 13, 2020, the company announced another dividend plan of 0.76 yuan per 10 shares along with a similar bonus issue of 5 shares for every 10 shares held [4]

Group 1 - The second "Golden Unicorn Best Investment Advisor" selection is underway, focusing on identifying outstanding investment advisors in wealth management [1] - The weekly ranking data from July 14 to July 20 shows that Wang Weilong from Bank of China Securities achieved the highest weekly return of 20.22% in stock simulation trading [1][2] - In the ETF simulation trading group, Sun Baoyan from Xinda Securities topped the list with a weekly return of 10.81% [2][3] Group 2 - In the public fund simulation configuration group, Sun Baoyan also led with a weekly return of 10.91%, followed by He Weidong from Dongxing Securities with 5.88% [3][5] - The social service evaluation highlights top advisors based on their IP homepage and simulated portfolio heat values, with Mei Xingxia from Dongfang Securities leading in IP homepage heat value [11]

Core Insights - The Sci-Tech Innovation Board (STAR Market) has significantly optimized the A-share market structure and serves as a crucial platform for tackling key core technologies since its launch on July 22, 2019 [1][6] - As of July 22, 2025, a total of 591 companies have been listed on the STAR Market, raising a cumulative 927.156 billion yuan in IPO funds, with a total market capitalization exceeding 7 trillion yuan [1][6] Underwriting and Market Performance - A total of 65 securities firms have provided underwriting and sponsorship services for the 591 STAR Market companies, with Guotai Junan leading with 112 underwritings, followed by CITIC Securities with 99 [1][2] - The top five firms by underwriting amount are Guotai Junan (213.777 billion yuan), CITIC Securities (167.069 billion yuan), CICC (130.254 billion yuan), CITIC Jinpu (88.015 billion yuan), and Huatai Securities (62.288 billion yuan) [2][4] East Asia Securities Case - Dongxing Securities, ranked around 20th in the competitive landscape, has sponsored 7 IPOs, accumulating an underwriting amount of 4.985 billion yuan, but faced significant reputational damage due to the fraudulent issuance case of Zeda Yisheng [5][6] - Zeda Yisheng was the first company to be forced to delist due to major violations, with its fraudulent activities inflating revenue by 342 million yuan and profits by 187 million yuan during its IPO period [5][6] - Following the Zeda Yisheng incident, Dongxing Securities has not sponsored any IPOs on the STAR Market since August 27, 2021, and has faced a 100% withdrawal rate for its IPO projects in 2024 [6][7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：601198 证券简称：东兴证券 公告编号：2025-030 东兴证券股份有限公司 2025 年度第二期短期融资券发行结果公告 东兴证券股份有限公司2025年度第二期短期融资券已于2025年7月23日发行 完毕，相关发行情况如下： | 债券名称 | | | 东兴证券股份有限公司 | | 2025 年度第二期短期融资券 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券简称 | 25 | 东兴证券 | | CP002 | 债券代码 | 072510138 | | | | | 发行日 | 2025 | 年 7 | 月 22 | 日 | 起息日 | 年 2025 | 月 7 | 23 | 日 | | 兑付日 | 2026 | 年 5 | 月 22 | 日 | 期限 | 303 天 | | | | | 计划发行总额 | 人民币 | 10 | 亿元 | | 实际发行总额 | 人民 ...

截至公告披露日，上海科惠股权投资中心(有限合伙)持有华新环保24,000,000股，占公司总股本的比例 为7.92%，占剔除公司回购专用账户股份后总股本比例为7.96%。上述股份为公司首次公开发行股票前 已发行的股份。 中国经济网北京7月23日讯华新环保（301265）(301265.SZ)昨日晚间披露《关于持股5%以上股东减持股 份的预披露公告》。 根据公告，股东上海科惠股权投资中心(有限合伙)计划自减持计划公告之日起15个交易日之后3个月内 通过集中竞价交易方式减持公司股份，减持数量合计不超过4,800,000股，占公司总股本的1.58%，占剔 除公司回购专用账户股份后总股本的1.59%。上海科惠股权投资中心(有限合伙)属于基金业协会备案的 符合条件的创投基金，其通过集中竞价交易方式减持股份总数不受比例限制。 今年一季报显示，上海科惠股权投资中心(有限合伙)为公司第四大股东。 华新环保首次公开发行股票募集资金总额为100,596.00万元，募集资金净额为92,537.25万元。华新环保 最终募集资金净额比原计划多41,537.25万元。华新环保于2022年12月12日发布的招股说明书显示，该公 司拟募集资 ...

相较第一季度，前十名发生了较大变化。申万宏源综合分数从一季度的第六位跃升至第一位，合并后的国泰海通也进入榜单前十。还有国投证券、东兴 证券也顺利跻身前十。而东吴证券、国金证券、东方财富则跌出了前十榜单。 据了解，证券公司执业质量评价体系主要包括专业质量得分和合规质量扣分，在基础分值100分之上进行增加和扣减，最终以合计分值进行排名。 独立财经评论员郭施亮在接受《国际金融报》记者采访时表示，券商在执业质量中获得好的评价，有利于提升券商机构的品牌知名度与综合竞争力，部 分中小券商通过这种方式实现弯道超车，也是提升自身竞争力与影响力的有力手段。 头部券商凭借深厚的业务积累和专业优势，在排名中占据前列，部分中小券商也凭借细分赛道的竞争优势排名靠前。 近日，北京证券交易所、全国股转公司发布2025年第二季度证券公司执业质量评价结果。 评价结果显示，在此次评价的103家券商中，申万宏源以149.3的合计分值位居各券商榜首。国投证券等8家券商分值高于120分，银河证券等21家券商分 值在110分至120分之间，湘财证券等72家券商分值在100分至110分之间。 | | | | | | | | | 专业质量得分 | | | ...

Core Viewpoint - The evaluation results of the securities companies' practice quality for the second quarter of 2025 have been released, highlighting significant changes in the rankings of the top ten firms, with Shenwan Hongyuan taking the lead [1][2]. Group 1: Evaluation Results - A total of 103 securities firms were evaluated, with Shenwan Hongyuan scoring 149.30 to rank first [1][2]. - The top ten firms also include Guotou Securities, Dongxing Securities, CITIC Jianan, CITIC Securities, Kaiyuan Securities, Guotai Junan, Guosen Securities, Huatai Securities, and Galaxy Securities [1][2]. - Compared to the first quarter, Shenwan Hongyuan rose from sixth to first place, while Guotai Junan entered the top ten after merging [2]. Group 2: Business Performance - In the area of sponsorship business quality scores at the Beijing Stock Exchange, Shenwan Hongyuan, Guotou Securities, and Dongxing Securities tied for first with a score of 16 [2]. - In the M&A business quality scores, Shenwan Hongyuan and Dongxing Securities both scored over 12 [2]. - In market-making business quality, CITIC Securities led with a score of 4.92 [2]. Group 3: Compliance Issues - Six securities firms were recorded with negative practice quality behaviors, involving issues in information disclosure and compliance [3]. - Specific penalties included public reprimands, warning letters, and requests for written commitments from involved parties [3]. - A case highlighted involved a company failing to disclose accurate sales agreements, leading to warnings for both the company and its sponsor [3]. Group 4: Information Disclosure Standards - In the first half of 2025, the Beijing Stock Exchange received applications from 115 companies for public offerings, with 6 successfully listed, raising a total of 1.923 billion yuan [4]. - The exchange emphasized the importance of accurate and complete information disclosure, warning that errors could lead to regulatory actions [5]. - The standards for listing have not changed, and companies must meet all requirements to apply for public offerings [4][5].